Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5168338 | 0.82 | KDM4E (0.40) | KDM4EJAK2LMNAGAAMAPT | |
| SCHEMBL10536881 | 0.82 | KDM4E (0.40) | KDM4EJAK2LMNAGAAMAPT | |
| SCHEMBL7690167 | 0.82 | KDM4E (0.46) | KDM4EJAK2LMNAGAAMAPT | |
| SCHEMBL9798227 | 0.80 | KDM4E (0.36) | KDM4EJAK2LMNAGAAMAPT | |
| SCHEMBL3472110 | 0.79 | NPC1 (0.42) | KDM4EJAK2LMNAGAAMAPT | |
| SCHEMBL525307 | 0.78 | KDM4E (0.34) | KDM4EJAK2LMNAGAAMAPT | |
| SCHEMBL7474927 | 0.76 | KDM4E (0.43) | KDM4EJAK2LMNAGAAMAPT | |
| SCHEMBL9217603 | 0.76 | KDM4E (0.33) | KDM4EJAK2LMNAGAAMAPT | |
| SCHEMBL790910 | 0.76 | CYP1A2 (0.37) | KDM4EJAK2LMNAGAAMAPT | |
| SCHEMBL93705 | 0.76 | ALDH1A1 (0.56) | KDM4EGAAMAPTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044070-B2 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2011-10-25 | — | — | US | disclosed |
| US-20100210637-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | MSD K.K. (JP) | 2010-08-19 | — | — | US | disclosed |
| US-7595316-B2 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-09-29 | — | — | US | disclosed |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2006-08-10 | — | — | US | disclosed |
| CN-1812981-A | Heteroaryloxy nitrogenous saturated heterocyclic derivative | BANYU PHARMA CO LTD (JP) | 2006-08-02 | — | — | CN | disclosed |
| EP-1642898-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-04-05 | — | — | EP | disclosed |
| EP-1304325-A1 | 5-(M-CYANOBENZYLAMINO)PYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-04-23 | — | — | EP | disclosed |
| EP-0929535-A4 | PROCESS AND NOVEL INTERMEDIATES | LILLY CO ELI (US) | 2001-05-23 | — | — | EP | disclosed |
| EP-0792875-B1 | Cryptophycin derivatives and their use as anti-microtubule agents | LILLY CO ELI (US) | 2001-05-09 | — | — | EP | disclosed |
| EP-0929535-A1 | PROCESS AND NOVEL INTERMEDIATES | ELI LILLY AND COMPANY (US) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998009955-A1 | PROCESS AND NOVEL INTERMEDIATES | ELI LILLY AND COMPANY (US) | 1998-03-12 | — | — | WO | disclosed |
| EP-0792875-A1 | Cryptophycin derivatives and their use as anti-microtubule agents | ELI LILLY AND COMPANY (US) | 1997-09-03 | — | — | EP | disclosed |
| EP-0735819-A4 | NEW CRYPTOPHYCINS | UNIV HAWAII (US) | 1997-03-19 | — | — | EP | disclosed |
| EP-0735819-A1 | NEW CRYPTOPHYCINS | UNIVERSITY OF HAWAII (US) | 1996-10-09 | — | — | EP | disclosed |
| WO-1995017093-A1 | NEW CRYPTOPHYCINS | UNIVERSITY OF HAWAII (US) | 1995-06-29 | — | — | WO | disclosed |
| US-4678792-A | ANTITHROMBIC AGENTS | DR. KARL THOMAE GMBH (DE) | 1987-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | HRH3, HRH4, HCRTR2 | KDM4E 1047/4885JAK2 394/4885LMNA 3909/4885 |
| US-20100210637-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | HRH3, HRH4, HRH2 | KDM4E 1384/4885JAK2 581/4885LMNA 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.